Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) management will conduct a conference call for 5th November 2020 at 4:30 PM Eastern Time to discuss financial results and companys performance for 3Q20.
The conference call will also be available live on the website www.dicerna.com
Earnings Expectation
Dicerna Pharmaceuticals, Inc. is reporting third quarter earnings results on Thursday 5th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.2 per share from $ 51.50 million in revenue. For the full year, analysts predict revenues of $ 203.03 million, while looking forward to loss of $ 0.81 per share.
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. Its principal development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and a program for an undisclosed rare liver disease.
